title: Outcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries.
abstract: Mantle cell lymphoma (MCL) has an aggressive clinical course with a median survival < 3 years and is incurable with conventional chemotherapy. A large multicentre study with adequate follow-up may clarify the role of significant factors affecting outcome in autologous stem cell transplantation for MCL. Patients receiving an autologous transplant for MCL between 1988 and 1998, and reported to the European Blood and bone Marrow Transplant (EBMT) registry or Autologous Blood and Marrow Transplant Registry (ABMTR), were included. Expert haematopathology review was required on all identified patients. Disease and transplant details were requested from the transplant centres, and the final cohort of patients with verified pathology, adequate clinical information and follow-up was analysed. One hundred and ninety-five patients were included in the analyses (149 EBMT, 46 ABMTR) with a median follow-up of 3.9 years. The 2 year and 5 year overall survival were 76% and 50%, and progression free survival was 55% and 33% respectively. Disease status at transplant was the most significant factor affecting survival: patients with chemosensitive disease but not in first complete remission (CR1) were 2.99 times (95% CI: 1.66-5.38, P < 0.001) more likely to die than patients transplanted in CR1. Autologous transplantation probably improves survival in patients with MCL especially if performed in first CR.
authors.affiliation: Department of Haematology, St James Hospital, Dublin, Ireland. evdb@eircom.net
authors.forename: Elisabeth
authors.initials: E
authors.lastname: Vandenberghe
authors.forename: Carmen
authors.initials: C
authors.lastname: Ruiz de Elvira
authors.forename: Fausto R
authors.initials: FR
authors.lastname: Loberiza
authors.forename: E
authors.initials: E
authors.lastname: Conde
authors.forename: A
authors.initials: A
authors.lastname: López-Guillermo
authors.forename: C
authors.initials: C
authors.lastname: Gisselbrecht
authors.forename: F
authors.initials: F
authors.lastname: Guilhot
authors.forename: Julie M
authors.initials: JM
authors.lastname: Vose
authors.forename: Koen
authors.initials: K
authors.lastname: van Biesen
authors.forename: J Douglas
authors.initials: JD
authors.lastname: Rizzo
authors.forename: Dennis D
authors.initials: DD
authors.lastname: Weisenburger
authors.forename: Peter
authors.initials: P
authors.lastname: Isaacson
authors.forename: Mary M
authors.initials: MM
authors.lastname: Horowitz
authors.forename: Anthony H
authors.initials: AH
authors.lastname: Goldstone
authors.forename: Hillard M
authors.initials: HM
authors.lastname: Lazarus
authors.forename: Norbert
authors.initials: N
authors.lastname: Schmitz
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D018572:Disease-Free Survival; D005260:Female; D006085:Graft Survival; D006801:Humans; D020522:Lymphoma, Mantle-Cell / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D012042:Registries; D033581:Stem Cell Transplantation / Q000379:methods*; D016019:Survival Analysis; D019172:Transplantation Conditioning / Q000379:methods; D014182:Transplantation, Autologous; D016896:Treatment Outcome